HIA
SYRE icon

Harbor Investment Advisory’s Spyre Therapeutics SYRE Stock Holding History

Harbor Investment Advisory’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$60K Buy
+674
New +$64.8K ﹤0.01% 722

Other funds holding SYRE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Harbor Investment Advisory's SYRE Position: Q3 2026 in Review

Harbor Investment Advisory opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 674 shares worth $60K. The stake represents ﹤0.01% of the portfolio and ranks #722 among its holdings.

9 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Harbor Investment Advisory held 674 shares of Spyre Therapeutics worth $60K as of Q3 2026.
  • Spyre Therapeutics was a new Harbor Investment Advisory position in Q3 2026.
  • Spyre Therapeutics made up ﹤0.01% of Harbor Investment Advisory's portfolio in Q3 2026, its #722 holding.
  • 9 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Harbor Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.